Effects of Atorvastatin Versus Probucol on Small Dense LDL

• Status: Completed
• Trial end date: 2007-05-01
• Target enrollment: 0
• Participant gender: All

Summary

Small dense low-density lipoprotein (LDL) plays an important role in causing glomerular injury through conversion to an oxidatively modified form of LDL. However, few studies evaluated the effects of antilipidemic agents on the LDL particle size and renoprotective actions in hyperlipidemic patients with non-diabetic nephropathy.

• Phase: Phase 4
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Yokohama City University Medical Center
• Treatments: Atorvastatin; Atorvastatin Calcium; Probucol

Criteria

Inclusion Criteria:

• Hyperlipidemic patients with non-diabetic nephropathy

Exclusion Criteria:

• Endocrinological, hematological or hepatic disease

• Cerebral infarction or hemorrhage

• Homozygous familial hypercholesterolemia

• Uncontrolled hypertension

• Myocardial infarction occurring within the previous 6 months

• Unstable angina

• Diabetic nephropathy

• Abnormal thyroid function

• Receiving steroids or immunosuppressive agents